Clinical trials: Schizophrenia Disorder
Schizophrenia
A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia
The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and safety of paliperidone palmitate in participants with schizophrenia (psychiatric…
- Trial name
- NCT01606254
- Testing
- Paliperidone palmitate
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia
Study of Three Doses of Aripiprazole in Patients With Acute Schizophrenia
A study to evaluate three doses of aripiprazole versus placebo in patients with an acute episode of schizophrenia
- Trial name
- NCT00080327
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 370 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Safety and Tolerability Study of Oral OPC-34712 as Maintenance Treatment in Adults With Schizophrenia
The purpose of this study is to assess the long-term safety, tolerability and efficacy of oral OPC-34712 as monotherapy in adults with schizophrenia.
- Trial name
- ZENITH (NCT01397786)
- Testing
- OPC-34712
- Where
- 148 sites in United States, Canada and 17 more
- Volunteers
- 1,044 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Treatment of Schizophrenic Patients With Ziprasidone
To determine whether ziprasidone provides good efficacy and tolerability in the treatment of schizophrenic Greek patients.
- Trial name
- TRITON (NCT00579670)
- Testing
- Ziprasidone
- Where
- 20 sites in Greece
- Volunteers
- 450 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia
Study to Evaluate the Efficacy and Safety of Armodafinil as Adjunctive Therapy in Adults With Schizophrenia
The primary objective of the study is to evaluate whether armodafinil treatment is more effective than placebo as adjunctive therapy to antipsychotic medication in alleviating the negative symptoms of schizophrenia
- Trial name
- NCT00772005
- Testing
- armodafinil
- Where
- 39 sites in United States
- Volunteers
- 287 people
- Sponsor
- Cephalon
Schizophrenia
A Long-Term Study of MP-214 in Patients With Chronic Phase or Elderly Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with chronic phase or elderly schizophrenia.
- Trial name
- NCT01625897
- Testing
- MP-214, Risperidone
- Where
- Japan
- Volunteers
- 125 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia, Psychotic Disorders
A Comparison of the Effectiveness and Safety of Injectable Risperidone With That of Risperidone Tablets in the Treatment of Patients With Chronic Schizophrenia
The primary purpose of the study is to show that treatment with an injectable formulation of risperidone is not less effective than and has a similar safety profile to risperidone tablets in patients with chronic schizophrenia.
- Trial name
- NCT00249223
- Testing
- Risperidone Long acting injectable
- Volunteers
- 641 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia
Effectiveness of Atypical Antipsychotics on Anhedonic Features in Patients With Schizophrenia
This prospective, multi-center, 12 weeks naturalistic NIS trial will be conducted in 25 hospitals in naturalistic treatment setting.
- Trial name
- PLEASURE (NCT01160679)
- Where
- 12 sites in South Korea
- Volunteers
- 231 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
Open-label Trial Characterizing the PK of 3 SC Olanzapine Extended-release Formulations in Participants With Schizophrenia/Schizoaffective Disorder
The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine. A secondary objective is to evaluate the safety and tolerability of 3 formulations of olanzapine.
- Trial name
- NCT06319170
- Testing
- Olanzapine Extended Release, Olanzapine Immediate Release
- Where
- 5 sites in United States
- Volunteers
- 106 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Schizophrenia
Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use
The purpose of the study is to determine whether there is an increased all-cause mortality in sertindole-treated patients in comparison to patients treated with a well-known antipsychotic (risperidone) when used under normal…
- Trial name
- SCoP (NCT00856583)
- Testing
- Sertindole, Risperidone
- Volunteers
- 9,809 people
- Sponsor
- H. Lundbeck A/S
Schizophrenia
A Study to Assess the Safety, Tolerability and Pharmacokinetics of XEP527 in Patients With Stable Schizophrenia
This study is designed to assess the safety and tolerability of the effects of XEP527, with particular emphasis on disease status and its compatibility with the standard of care in patients with stable schizophrenia.
- Trial name
- NCT07908680
- Testing
- XEP527
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Cognitive Impairment Associated With Schizophrenia
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS)
The primary objective of the study is to evaluate the efficacy of BIIB104 in participants with CIAS, using the Working Memory Domain of the MATRICS Consensus Cognitive Battery (MCCB).
- Trial name
- TALLY (NCT03745820)
- Testing
- BIIB104
- Where
- 60 sites in United States, Germany and 3 more
- Volunteers
- 195 people
- Sponsor
- Biogen
Schizophrenia, Schizoaffective Disorder
Validity of the Spanish Version of Subjective Well-being Under Neuroleptics Scale (SWN-K) in Patients With Schizophrenia
Observational, short-term prospective, multicenter study to assess psychometric properties of the Spanish version of SWN-K scale in patients with schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- SWN-K (NCT00749970)
- Where
- 14 sites in Spain
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Schizophrenia
Long-Term Study of MP-214 in Patients With Schizophrenia
The objective of this study is to evaluate the long-term safety, tolerability, and efficacy of MP-214 in patients with schizophrenia.
- Trial name
- NCT01626872
- Testing
- MP-214 3mg, MP-214 6mg, MP-214 9mg
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 254 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia
Safety, Tolerability, and Pharmacokinetics of Switching From Oral Risperidone to Risperidone Implant
This is an Open-Label Study in Stable Schizophrenia Patients to Evaluate the Safety, Tolerability, and Pharmacokinetics of Switching from Oral Risperidone to Risperidone Implant (DLP-114).
- Trial name
- DLP-114 (NCT04418466)
- Testing
- Risperidone
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Delpor, Inc.
Smoking Cessation
Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder
Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.
- Trial name
- NCT00644969
- Testing
- varenicline (CP-526,555)
- Where
- 14 sites in United States, Canada
- Volunteers
- 128 people
- Sponsor
- Pfizer
Schizophrenia
Treatment of Patients With Recently Exacerbated Schizophrenia With Paliperidone Palmitate
The purpose of this study is to explore the efficacy of paliperidone palmitate administered as a once monthly injection in patients with an acute exacerbation of schizophrenia.
- Trial name
- NCT01448720
- Testing
- Paliperidone palmitate
- Where
- 12 sites in Brazil, Colombia and 1 more
- Volunteers
- 142 people
- Sponsor
- Janssen-Cilag Farmaceutica Ltda.
Schizophrenia
A Phase 2 Efficacy and Safety Study of TAK-063 in Participants With an Acute Exacerbation of Schizophrenia
The purpose of this study is to evaluate the efficacy, safety and tolerability of TAK-063 compared with placebo in treatment of acutely exacerbated schizophrenia.
- Trial name
- NCT02477020
- Testing
- TAK-063 20 mg
- Where
- 15 sites in United States
- Volunteers
- 164 people
- Sponsor
- Takeda
Schizoaffective Disorder, Psychotic Disorder
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
The purpose of this study is to measure the effectiveness and assess the safety of two dosages of the antipsychotic paliperidone extended-release (ER) in patients who are experiencing an acute episode of schizoaffective disorder.
- Trial name
- NCT00397033
- Testing
- Paliperidone ER
- Volunteers
- 316 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users
This study uses existing health records and insurance claims data to understand how adults in the United States are treated with KarXT, a medication for schizophrenia.
- Trial name
- NCT07571148
- Testing
- KarXT (xanomeline and trospium)
- Where
- United States
- Volunteers
- 6,876 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.